Cargando…

Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers

Ado-trastuzumab emtansine (T-DM1) is an antibody–drug conjugate approved by the FDA in 2013 for advanced HER2-positive breast cancer treatment exhibiting promising clinical benefits. However, HER2 overexpression and gene amplification have also been reported in other cancers like gastric cancer, non...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Yang, Zou, Jiayu, Sun, Chen, Peng, Fu, Peng, Cheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Molecular Biosciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10210145/ https://www.ncbi.nlm.nih.gov/pubmed/37251081 http://dx.doi.org/10.3389/fmolb.2023.1165781

Ejemplares similares

Ado-Trastuzumab Emtansine in Metastatic HER2-Positive Breast Cancer
por: Callahan, Rena
Publicado: (2014)

Whether HER2-positive non-breast cancers are candidates for treatment with Ado-trastuzumab emtansine?
por: Moghaddas, Azadeh, et al.
Publicado: (2016)

Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer
por: Magalhães, Marcos Aurélio Fonseca, et al.
Publicado: (2022)

Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer
por: Spring, Laura M., et al.
Publicado: (2021)

ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer
por: Griguolo, Gaia, et al.
Publicado: (2020)

HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer
por: Venetis, Konstantinos, et al.
Publicado: (2022)

Mir-4728 is a Valuable Biomarker for Diagnostic and Prognostic Assessment of HER2-Positive Breast Cancer
por: Rui, Tao, et al.
Publicado: (2022)

Long-time Response with Ado-trastuzumab Emtansine in a Recurrent Metastatic Breast Cancer
por: Manthri, Sukesh, et al.
Publicado: (2019)

Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab
por: Corrêa, Tatiana Strava, et al.
Publicado: (2018)

Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
por: Oostra, Drew R, et al.
Publicado: (2014)

Editorial: Ferroptosis in cancer and beyond
por: Wang, Xin, et al.
Publicado: (2023)

Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine
por: Sadeghi, Saeed, et al.
Publicado: (2014)

Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine
por: Recondo, Gonzalo, et al.
Publicado: (2016)

Monitoring T Cells Responses Mounted by Therapeutic Cancer Vaccines
por: Lim, Kue Peng, et al.
Publicado: (2021)

Editorial: Cancer Treatment and Early Detection Targeting HER Receptors
por: Cai, Xiaoqing, et al.
Publicado: (2022)

Pathological identification of HER2-low breast cancer: Tips, tricks, and troubleshooting for the optimal test
por: Sajjadi, Elham, et al.
Publicado: (2023)

In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate
por: Chen, Liuxi, et al.
Publicado: (2016)

Editorial: Ferroptosis in cancer and Beyond—volume II
por: Wang, Xin, et al.
Publicado: (2023)

Editorial: Cancer treatment and early detection targeting HER receptors, Volume II
por: Cai, Xiaoqing, et al.
Publicado: (2023)

Moving HER2-low breast cancer predictive and prognostic data from clinical trials into the real world
por: Di Cosimo, Serena, et al.
Publicado: (2022)

tRNA Metabolism and Lung Cancer: Beyond Translation
por: Bian, Meng, et al.
Publicado: (2021)

Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
por: Sawaki, Masataka
Publicado: (2014)

Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
por: Hunter, Francis W., et al.
Publicado: (2019)

Progress in the Research and Targeted Therapy of ErbB/HER Receptors in Urothelial Bladder Cancer
por: Chen, Dong, et al.
Publicado: (2021)

Evaluation of PIK3CA mutations in advanced ER+/HER2-breast cancer in Portugal – U-PIK Project
por: Peixoto, Ana, et al.
Publicado: (2023)

Within and Beyond the Nucleotide Addition Cycle of Viral RNA-dependent RNA Polymerases
por: Gong, Peng
Publicado: (2022)

A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
por: Patel, Tejal A., et al.
Publicado: (2019)

Impact of Pertuzumab and Ado-Trastuzumab Emtansine on Cumulative Avoidance of Recurrence Among Women Treated for Locally Advanced, Inflammatory, or Early-Stage Nonmetastatic HER2-Positive Breast Cancer in the United States
por: Sussell, Jesse A., et al.
Publicado: (2023)

Ado-Trastuzumab Emtansine-Induced Pulmonary Toxicity: A Single-Institution Retrospective Review
por: Egloff, Heidi, et al.
Publicado: (2018)

Excellent Response with Ado-Trastuzumab Emtansine in a Patient with Relapsed Metastatic Breast Cancer Presenting with Pulmonary Lymphangitic Carcinomatosis
por: Yu, Zhou, et al.
Publicado: (2017)

Molecular imaging of HER2 receptor: Targeting HER2 for imaging and therapy in nuclear medicine
por: Miladinova, Daniela
Publicado: (2023)

Breast Cancer Subtypes Based on Hypoxia-Related Gene Sets Identify Potential Therapeutic Agents
por: Xiong, Zhenchong, et al.
Publicado: (2022)

YES1 amplification confers trastuzumab–emtansine (T-DM1) resistance in HER2-positive cancer
por: Wang, Lei, et al.
Publicado: (2020)

MicroRNAs: Important Players in Breast Cancer Angiogenesis and Therapeutic Targets
por: Hussen, Bashdar Mahmud, et al.
Publicado: (2021)

STAT3 activation confers trastuzumab‐emtansine (T‐DM1) resistance in HER2‐positive breast cancer
por: Wang, Lei, et al.
Publicado: (2018)

Case Report: Collapsing Focal Segmental Glomerulosclerosis After Initiation of Ado-Trastuzumab Emtansine Therapy
por: Hakroush, Samy, et al.
Publicado: (2021)

Editorial: Ras and Other GTPases in Cancer: From Basic to Applied Research
por: Cho, Kwang-jin, et al.
Publicado: (2021)

Breast Cancer; Discovery of Novel Diagnostic Biomarkers, Drug Resistance, and Therapeutic Implications
por: Afzal, Samia, et al.
Publicado: (2022)

Editorial: Breast cancer resistance, biomarkers and therapeutics development in the era of artificial intelligence
por: Khan, Abbas, et al.
Publicado: (2022)

Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Treatments After T-DM1 in the United States
por: Denduluri, Neelima, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_urb0ct75mg52sdmj6dcd00j0k7